Global Stable Isotope Labeled Compounds Market Size By Type (Deuterium, Oxygen-18, Carbon-13, Nitrogen-15), By End-Use (Research Institutes, Pharmaceutical & Biopharmaceutical), By Geographic Scope And Forecast

Stable Isotope Labeled Compounds Market size was valued at USD 278.23 Million in 2021 and is projected to reach USD 383.51 Million by 2030 , growing at a CAGR of 3.64% from 2023 to 2030. The growth of this market is majorly driven by factors such as the increase in research activities in the pharmaceutical and biotechnology sector. Also, the rising prevalence of cancer has fuelled research activities using such stable isotope-labeled compounds. The Global Stable Isotope Labeled Compounds Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Stable Isotope Labeled Compounds Market Definition

Stable isotope labeling includes the use of non-radioactive isotopes which can serve as tracers used to model different chemical and biochemical systems. The isotope can act as an identifiable label on that compound through nuclear magnetic resonance (NMR) and mass spectrometry (MS). The Commonly used stable isotopes include 2H, 13C, and 15N. Stable isotope-labeled compounds have generated considerable interest among researchers engaged in metabolism-mediated toxicity studies. Their role has risen to insignificance in the assessment of in vivo metabolism in a vast range of metabolic research. Apart from metabolomics studies, stable isotope-labeled compounds are being increasingly used in environmental analysis, proteomics, and medical diagnostic research.

Global Stable Isotope Labeled Compounds Market Overview

The report's market outlook section primarily encompasses essential market dynamics, drivers, restraints, opportunities, and challenges the trade faces. Drivers and restraints are intrinsic factors, whereas opportunities and challenges are extrinsic factors of the market.

The growth of this market is majorly driven by factors like the rise in analysis activities within the pharmaceutical and biotechnology sector. Also, the rising prevalence of cancer has fuelled analysis activities using such stable isotope-labeled compounds. Moreover, the increase at intervals in the Stable Isotope Labeled Compounds Market due to the rise in analysis activity, significantly at intervals in the area of customized medicine and medicines, presents a superb chance for the Stable Isotope Labeled Compounds Market to grow healthy over the forecast amount. However, implementing stable isotope-labeled compounds needs high capital investments, which is the most critical barrier to plug growth.

Verified analysis narrows down their data exploitation of primary sources to validate the knowledge and use it in the aggregation of a full-fledged analysis study. The report contains a quantitative and qualitative estimation of market parts that interest the consumer. The "Global Stable Isotope Labeled Compounds Market" is split into sub-segments that can provide classified knowledge regarding the most recent trends at intervals.

Global Stable Isotope Labeled Compounds Market: Segmentation Analysis

The Global Stable Isotope Labeled Compounds Market is Segmented on the basis of Type, End-Use, and Geography.

Stable Isotope Labeled Compounds Market, By Type

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15

Based on Type, the market is segmented into Deuterium, Oxygen-18, Carbon-13, and Nitrogen-15. Deuterium accounted for the largest market share in 2019 followed by Oxygen-18. Deuterium-labeled compounds have been utilized efficiently by toxicologists and drug metabolism scientists to gain an understanding of drug disposition and the potential performance of these compounds in the target organ toxicities.

Stable Isotope Labeled Compounds Market, By End-Use

Research Institutes
Pharmaceutical & Biopharmaceutical
Others

Based on End-Use, the market is segmented into Research Institutes, Pharmaceutical & Biopharmaceutical, and Others. Research Institutes accounted for the largest market share in 2019. Government research institutes, medical research institutes, and academic research institutes employ stable isotope-labeled compounds for performing metabolomics and proteomics research studies.

Stable Isotope Labeled Compounds Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Regional Analysis, the Global Stable Isotope Labeled Compounds Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is the major contributor to the Stable Isotope Labeled Compounds Market partly due to the prevalence of cancer treatment and its research as well as the rising older population in the Americas.

Key Players

The "Global Stable Isotope Labeled Compounds Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
Merck KGaA, Cambridge Isotope Laboratories, Inc., PerkinElmer Inc., Medical Isotopes, Inc., Omicron Biochemicals, Inc., Taiyo Nippon Sanso Corporation, Isosciences, Trace Sciences International, Alsachim, Urenco Stable Isotopes.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with their product benchmark and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In July 2021, Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, has launched the first commercially available 12C-enriched methane-grade gas for quantum applications.
In July 2021, Bruker has entered into a partnership with Massachusetts-based Cambridge Isotope Laboratories (CIL), formalizing a long-term relationship between the two companies and further extending Bruker's capabilities to deliver end-to-end service solutions to its installed customer base in nuclear magnetic resonance (NMR) spectroscopy under the LabScape(R) brand.
In June 2020, Creative Proteomics, the main provider in proteomics and metabolomics services, delivered a few proteomics services to scientists. The assistance ranges incorporate four: iTRAQ naming help, name-free quantitation service, SILAC mass spectrometry service, and TMT proteomics service.
In June 2020, Cambridge Isotope Laboratories, (CIL) the largest manufacture and global supplier of stable isotopes and stable isotope-labeled compounds, collaborated with Alsachim to provide antiviral drug standards to researchers and clinicians exclusively in the Americas. These products are available through CIL in convenient packaging sizes and are adept for use as internal standards in therapeutic monitoring and quantitative analysis.
In December 2020, Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently began a significant capacity optimization of one of the production cascades at the 13C separation facility in Xenia, Ohio. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade's 13C production by 10%.
Merger & Acquisitions
In April 2018, TAIYO NIPPON SANSO CORPORATION totally acquired SAIL advances Inc., where it's valuable in assembling and conveying stable isotope-marked amino acids that are material in biotechnology-related businesses and the medication industry.

Product Code: 24354

1 INTRODUCTION OF GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY TYPE

5.1 Overview
5.2 Carbon-13
5.3 Nitrogen-15
5.4 Deuterium
5.5 Oxygen-18

6 GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY END-USE

6.1 Overview
6.2 Research Institutes
6.3 Pharmaceutical & Biopharmaceutical
6.4 Others

7 GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL STABLE ISOTOPE LABELED COMPOUNDS MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Merck KGaA
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Cambridge Isotope Laboratories, Inc.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 PerkinElmer Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Medical Isotopes, Inc.
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Omicron Biochemicals, Inc.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Taiyo Nippon Sanso Corporation
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Isosciences
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Trace Sciences International
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Alsachim
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Urenco Stable Isotopes
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments

10 KEY DEVELOPMENTS

10.1 Product Launches/Developments
10.2 Mergers and Acquisitions
10.3 Business Expansions
10.4 Partnerships and Collaborations

11 Appendix

11.1 Related Research